

Publications significatives de l'équipe 7, 2010 – 2017

François CM, Petit F, Giton F, Gougeon A, Ravel C, Magre S, Cohen-Tannoudji J, Guigon CJ. A novel action of follicle-stimulating hormone in the ovary promotes estradiol production without inducing excessive follicular growth before puberty. [Sci Rep. 2017 Apr 11;7:46222.](#)

Peyronnet B, Khene ZE, Pradère B, Seisen T, Verhoest G, Masson-Lecomte A, Grassano Y, Roumiguié M, Beauval JB, Baumert H, Droupy S, Doumerc N, Bernhard JC, Vaessen C, Bruyère F, de la Taille A, Rouprêt M, Bensalah K. Off-Clamp versus On-Clamp Robotic Partial Nephrectomy: A Multicenter Match-Paired Case-Control Study. [Study. Urol Int. 2017 Apr 6. doi: 10.1159/000471772](#)

Beauval JB, Cabarro B, Gandaglia G, Patard PM, Ouzzane A, de la Taille A, Soulié M, Briganti A, Ploussard G, Rozet F, Roumiguié M. External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. [Prostate. 2017 Jun;77\(8\):928-933](#)

Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, Briganti A, Karakiewicz P, Seitz C, Salomon L, de la Taille A, Rouprêt M, Graefen M, Shariat SF. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. [Prostate Cancer Prostatic Dis. 2017 Jun;20\(2\):197-202](#)

Corbineau S, Lassalle B, Givelet M, Souissi-Sarahoui I, Firlej V, Romeo PH, Allemand I, Riou L, Fouchet P. Spermatogonial stem cells and progenitors are refractory to reprogramming to pluripotency by the transcription factors Oct3/4, c-Myc, Sox2 and Klf4. [Oncotarget. 2017 Feb 7;8\(6\):10050-10063](#)

Lebacle C, Roudot-Thoraval F, Moktefi A, Bouanane M, De La Taille A, Salomon L. Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy. [World J Urol. 2016 Dec 19. doi: 10.1007/s00345-016-1981-5](#)

Beauval JB, Ploussard G, Cabarro B, Roumiguié M, Ouzzane A, Gas J, Goujon A, Marcq G, Mathieu R, Vincendeau S, Cathelineau X, Mongiat-Artus P, Salomon L, Soulié M, Méjean A, de La Taille A, Rouprêt M, Rozet F; Committee of Cancerology of the Association of French Urology.. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. [World J Urol. 2016 Dec 16. \[Epub ahead of print\] PubMed PMID: 27987030](#)

Rousseau B, Kempf E, Desamericq G, Boissier E, Chaubet-Houdu M, Joly C, Saldana C, BouSSION H, Neuzillet C, Macquin-Mavier I, Oudard S, Salomon L, de la Taille A, Tournigand C. First-line antiangiogenics for metastatic renal cellcarcinoma: A systematic review and network meta-analysis. [Crit Rev Oncol Hematol. 2016 Nov;107:44-53](#)

Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort. [Clin Genitourin Cancer. 2017 Feb;15\(1\):e45-e52](#)

Beauval JB, Roumiguié M, Filleron T, Benoit T, de la Taille A, Malavaud B, Salomon L, Soulié M, Ploussard G. Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer. [BMC Urol. 2016 Jun 8;16\(1\):26](#)

Masson-Lecomte A, López de Maturana E, Goddard ME, Picornell A, Rava M, González-Neira A, Márquez M, Carrato A, Tardon A, Lloreta J, Garcia-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N; SBC/EPICURO Study Investigators.. Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. [Cancer Epidemiol Biomarkers Prev. 2016 Jul;25\(7\):1144-50. doi: 10.1158/1055-9965.EPI-15-0894. Epub 2016 May 6. PubMed PMID: 27197286.](#)

Lazzeri M, Lughezzani G, Haese A, McNicholas T, de la Taille A, Buffi NM, Cardone P, Hurle R, Casale P, Bini V, Redorta JP, Graefen M, Guazzoni G. Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study. [Urol Oncol. 2016 Sep;34\(9\):415.e13-9. doi: 10.1016/j.urolonc.2016.04.003. Epub 2016 May 10. PubMed PMID: 27178729.](#)

Ploussard G, de la Taille A, Moulin M, Allorys Y, Abbou C, Salomon L. Conditional Disease-free Survival After Radical Prostatectomy: Recurrence Risk Evolution Over Time. [Urology. 2016 Aug;94:173-9. doi: 10.1016/j.urology.2016.04.031. Epub 2016 May 3. PubMed PMID: 27154046.](#)

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Lorient Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. [Ann Oncol. 2016 Jul;27\(7\):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18. PubMed PMID: 27091807.](#)

Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, Carpentier G, Semprez F, Céraline J, Allory Y, Courty J, De La Taille A, Vacherot F. Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. [Oncotarget. 2016 Oct 25;7\(43\):69397-69411. doi: 10.18632/oncotarget.8043. PubMed PMID: 26993766; PubMed Central PMCID: PMC5342486.](#)

de la Taille A, Martínez-Piñeiro L, Cabri P, Houchard A, Schalken J; Triptocare LT Study Group.. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy. [BJU Int. 2017 Jan;119\(1\):74-81. doi: 10.1111/bju.13455. Epub 2016 Mar 23. PubMed PMID: 26919403.](#)

Peyronnet B, Pradère B, De La Taille A, Bruyère F, Doumerc N, Droupy S, Vaessen C, Baumert H, Bernhard JC, Rouprêt M, Mejean A, Bensalah K. Postoperative drainage does not

prevent complications after robotic partial nephrectomy. [World J Urol. 2016 Jul;34\(7\):933-8. doi: 10.1007/s00345-015-1721-2. Epub 2015 Oct 28. PubMed PMID: 26511751.](#)

Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, Contremoulins I, Khodari M, Rodriguez AM, Augustin D, Roudot-Thoraval F, de la Taille A, Rouard H. Safety of Intracavernous Bone Marrow-Mononuclear Cells for Postradical Prostatectomy Erectile Dysfunction: An Open Dose-Escalation Pilot Study. [Eur Urol. 2016 Jun;69\(6\):988-91. doi: 10.1016/j.eururo.2015.09.026. Epub 2015 Oct 4. PubMed PMID: 26439886.](#)

Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, Mansuy L, Bastien C, de la Taille A, BouSSION H, Charpy C, Jourdain A, Bléchet C, Pierron G, Gentien D, Choudat L, Tournigand C, Delattre O, Allory Y, Bourdeaut F. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas. [Eur Urol. 2016 Jun;69\(6\):1055-61. doi: 10.1016/j.eururo.2015.09.027. Epub 2015 Oct 1. PubMed PMID: 26433572.](#)

Lebdai S, Basset V, Branchereau J, de La Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, Audenet F. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? [World J Urol. 2016 May;34\(5\):617-24. doi: 10.1007/s00345-015-1687-0. Epub 2015 Sep 15. Review. PubMed PMID: 26373956.](#)

Lebdai S, Delongchamps NB, Sapoval M, Robert G, Amouyal G, Thiounn N, Karsenty G, Ruffion A, de La Taille A, Descazeaud A, Mathieu R. Early results and complications of prostatic arterial embolization for benign prostatic hyperplasia. [World J Urol. 2016 May;34\(5\):625-32. doi: 10.1007/s00345-015-1665-6. Epub 2015 Aug 15. Review. PubMed PMID: 26276151.](#)

Albisinni S, Oderda M, Fossion L, Varca V, Rassweiler J, Cathelineau X, Chlosta P, De la Taille A, Gaboardi F, Piechaud T, Rimington P, Salomon L, Sanchez-Salas R, Stolzenburg JU, Teber D, Van Velthoven R. The morbidity of laparoscopic radical cystectomy: analysis of postoperative complications in a multicenter cohort by the European Association of Urology (EAU)-Section of Uro-Technology. [World J Urol. 2016 Feb;34\(2\):149-56. doi: 10.1007/s00345-015-1633-1. Epub 2015 Jul 2. PubMed PMID: 26135307.](#)

Giton F, Sirab N, Franck G, Gervais M, Schmidlin F, Ali T, Allory Y, Taille A, Vacherot F, Loric S, Fiet J. Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. [J Steroid Biochem Mol Biol. 2015 May 6;152:89-100.](#)

Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. [Cancer. 2015 May 1;121\(9\):1422-30.](#)

Masson-Lecomte A, Rava M, Real FX, Hartmann A, Allory Y, Malats N. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. [Eur Urol. 2014 Dec;66\(6\):1078-91.](#)

Terry S, El-Sayed IY, Destouches D, Maillé P, Nicolaiew N, Ploussard G, Semprez F, Pimpie C, Beltran H, Londoño-Vallejo A, Allory Y, de la Taille A, Salomon DS, Vacherot F. CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells

through parallel regulation of AKT and FGFR activities. [Oncotarget. 2014 Dec 26. \[Epub ahead of print\]](#)

Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C, López-Bigas N, Kamoun A, Neuzillet Y, Gestraud P, Grieco L, Rebouissou S, de Reyniès A, Benhamou S, Le Bret T, Southgate J, Barillot E, Allory Y, Zinovyev A, Radvanyi F. Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. [Cell Rep. 2014 Nov 20;9\(4\):1235-45.](#)

Terry S, Maillé P, Baaddi H, Kheuang L, Soyeux P, Nicolaiew N, Ceraline J, Firlej V, Beltran H, Allory Y, de la Taille A, Vacherot F. Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. [Neoplasia. 2013 Jul;15\(7\):761-72.](#)

Sirab N, Terry S, Giton F, Caradec J, Chimingqi M, Moutereau S, Vacherot F, de la Taille, Kouyoumdjian JC, Loric S. Androgens regulate Hedgehog signalling and proliferation in androgen-dependent prostate cells. [Int J Cancer. 2012 Sep 15;131\(6\):1297-306.](#)

Ploussard G, Terry S, Maillé P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. [Cancer Res. 2010 Nov 15;70\(22\):9253-64.](#)

Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N. Expression of follicle-stimulating hormone receptor in tumor blood vessels. [N Engl J Med. 2010 Oct 21;363\(17\):1621-30.](#)